Departure of European expert leaves a vacuum at the Commission, FDA official claims
This article was originally published in Clinica
The departure of medical devices expert Norbert Anselmann from the European Commission's industrial affairs unit is worrying FDA officials, who say it could hamper US efforts to prepare for the October 1 implementation of the mutual recognition agreement with the European Union.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.